ATE391496T1 - Geschmacksmaskierte pharmazeutische formulierungen - Google Patents

Geschmacksmaskierte pharmazeutische formulierungen

Info

Publication number
ATE391496T1
ATE391496T1 AT02723243T AT02723243T ATE391496T1 AT E391496 T1 ATE391496 T1 AT E391496T1 AT 02723243 T AT02723243 T AT 02723243T AT 02723243 T AT02723243 T AT 02723243T AT E391496 T1 ATE391496 T1 AT E391496T1
Authority
AT
Austria
Prior art keywords
flavor
masked pharmaceutical
pharmaceutical formulations
microcapsule
taste
Prior art date
Application number
AT02723243T
Other languages
English (en)
Inventor
Stephen Ulrich
Karen Zimm
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Application granted granted Critical
Publication of ATE391496T1 publication Critical patent/ATE391496T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT02723243T 2001-03-05 2002-02-26 Geschmacksmaskierte pharmazeutische formulierungen ATE391496T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US27347301P 2001-03-05 2001-03-05

Publications (1)

Publication Number Publication Date
ATE391496T1 true ATE391496T1 (de) 2008-04-15

Family

ID=23044085

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02723243T ATE391496T1 (de) 2001-03-05 2002-02-26 Geschmacksmaskierte pharmazeutische formulierungen

Country Status (11)

Country Link
US (1) US6767557B2 (de)
EP (1) EP1370247B1 (de)
JP (1) JP2004520420A (de)
AT (1) ATE391496T1 (de)
AU (1) AU2002254036A1 (de)
BR (1) BR0207932A (de)
CA (1) CA2440069A1 (de)
DE (1) DE60226012T2 (de)
MX (1) MXPA03008057A (de)
MY (1) MY129317A (de)
WO (1) WO2002069939A2 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004535370A (ja) * 2001-03-05 2004-11-25 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 味をマスクした液体製薬学的組成物
FR2821747B1 (fr) * 2001-03-09 2004-07-02 Ethypharm Lab Prod Ethiques Suspension de telithromycine a gout masque
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
MY140561A (en) * 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
JP4732696B2 (ja) * 2002-04-09 2011-07-27 フラメル・テクノロジー 活性成分の改変された放出のための、マイクロカプセルの水性懸濁液形態での経口医薬品製剤
ES2314227T7 (es) * 2002-04-09 2012-11-19 Flamel Technologies Formulacion farmaceutica oral en forma de suspension acuosa de microcapsulas que permiten la liberacion modificada de amoxilicina.
EA009985B1 (ru) 2003-03-10 2008-04-28 Никомед Гмбх Новый способ получения рофлумиласта
JP2007501810A (ja) * 2003-08-11 2007-02-01 メルク フロスト カナダ リミテツド 一段階被覆法を用いて作製された着香味遮蔽製薬製剤
US20060013834A1 (en) * 2004-02-24 2006-01-19 Medicis Pediatrics, Inc. Room temperature stable aqueous liquid pharmaceutical composition
US20060127479A1 (en) * 2004-10-08 2006-06-15 Natrajan Kumaraperumal Solvent free taste masked pharmaceutical compositions
ES2421916T3 (es) 2005-03-16 2013-09-06 Nycomed Gmbh Forma farmacéutica de sabor enmascarado que contiene roflumilast
US20060216355A1 (en) * 2005-03-28 2006-09-28 Donald Spector Encapsulated pharmaceuticals in a medium having non-encapsulated flavoring agents
EP1888025B1 (de) * 2005-06-08 2020-08-12 Basf Corporation Medikamententrägerzusammensetzung und verfahren zur bildung eines films daraus
US20070264335A1 (en) * 2006-05-09 2007-11-15 Sherman Bernard C Modified release tablets comprising tramadol
US20070281014A1 (en) * 2006-06-01 2007-12-06 Cima Labs, Inc. Prednisolone salt formulations
US8637076B2 (en) * 2006-06-01 2014-01-28 Cima Labs Inc. Prednisolone salt formulations
US8007783B2 (en) * 2006-08-22 2011-08-30 Carl Miller Quality of life for hepatitis C patients with a formulation for administration to the oral mucosa including Lactobacillus delbrueckii subsp. bulgaricus and N-acetyl D-glucosamine
US8304226B2 (en) * 2006-08-22 2012-11-06 Carl Miller Quality of life of hepatitis C patients with a formulation for administration to the oral mucosa including freeze dried lysate of selected Lactobacillus or Bifidobacterium species and N-acetyl D-glucosamine
WO2008098586A1 (en) * 2007-02-13 2008-08-21 Dafra Pharma N.V. Pharmaceutical carrier composition and pharmaceutical composition
RU2474417C2 (ru) * 2007-06-18 2013-02-10 Дольхаи Клиника Эгесшегюдьи Кфт. Биоцидные капсулы, содержащий их препарат и тампон, содержащий препарат
US20090065225A1 (en) * 2007-09-07 2009-03-12 Black & Decker Inc. Switchable anti-lock control
DK2403482T3 (en) * 2009-03-04 2018-03-05 Emplicure Ab ABUSE RESISTANT FORMULATION
WO2010128300A1 (en) 2009-05-08 2010-11-11 Aduro Materials Ab Composition for sustained drug delivery comprising geopolymeric binder
US20110236494A1 (en) * 2010-03-04 2011-09-29 Ranbaxy Laboratories Limited Ciprofloxacin oral suspension
CA2802142C (en) 2010-04-12 2020-03-10 S. Zhaveri Pharmakem Pvt. Ltd. Ciprofloxacin dry syrup composition
NZ608598A (en) 2010-09-07 2015-03-27 Orexo Ab A transdermal drug administration device
CN107049979B (zh) * 2011-09-30 2020-08-14 持田制药株式会社 易服用性固体制剂
US20140086849A1 (en) 2012-09-21 2014-03-27 Elizabeth McKenna Naturally-Occurring CpG Oligonucleotide Compositions and Therapeutic Applications Thereof
SG10202013014RA (en) 2012-01-16 2021-02-25 Mckenna Elizabeth Compositions and Methods for the Treatment of Hepatic Diseases and Disorders
US12268718B2 (en) 2012-01-16 2025-04-08 Labyrinth Holdings Llc Control of cellular redox levels
ES2761407T3 (es) 2013-03-15 2020-05-19 Aprecia Pharmaceuticals LLC Forma de dosificación rápidamente dispersable de topiramato
HK1213472A1 (zh) 2013-03-15 2016-07-08 阿普雷奇亚制药有限责任公司 奧卡西平的快速分散劑型
US10098964B2 (en) 2015-03-12 2018-10-16 The Board Of Trustees Of The University Of Illinois Inclusion complexes and methods for making the same
JP6294400B2 (ja) * 2016-07-19 2018-03-14 持田製薬株式会社 易服用性固形製剤
WO2020104837A1 (en) 2018-11-21 2020-05-28 Rosemont Pharmaceuticals Limited Oral topiramate suspension formulations with extended shelf stability and enhanced bioavailability
WO2020255837A1 (ja) 2019-06-17 2020-12-24 東和薬品株式会社 時限式溶出マスキング粒子およびそれを含有する経口医薬組成物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2068402C (en) 1991-06-14 1998-09-22 Michael R. Hoy Taste mask coatings for preparation of chewable pharmaceutical tablets
US5599556A (en) 1991-12-31 1997-02-04 Abbott Laboratories Prolamine coatings for taste masking
DE4200821A1 (de) 1992-01-15 1993-07-22 Bayer Ag Geschmacksmaskierte pharmazeutische mittel
DE19631084A1 (de) * 1996-08-01 1998-02-05 Basf Ag Verwendung von (Meth)acrylsäure-Copolymeren zur Erhöhung der Permeabilität der Schleimhaut
PT1121103E (pt) * 1998-05-18 2007-02-28 Takeda Pharmaceutical Comprimidos de desintegração oral compreendendo um benzimidazole
CN1161106C (zh) 1998-07-31 2004-08-11 大塚制药株式会社 具有改良味道的药物组合物
WO2000076479A1 (en) 1999-06-11 2000-12-21 Ranbaxy Laboratories Limited Taste masked compositions
IN192159B (de) 2000-05-15 2004-02-28 Ranbaxy Lab Ltd

Also Published As

Publication number Publication date
US6767557B2 (en) 2004-07-27
MY129317A (en) 2007-03-30
DE60226012T2 (de) 2009-05-14
EP1370247A2 (de) 2003-12-17
DE60226012D1 (de) 2008-05-21
JP2004520420A (ja) 2004-07-08
MXPA03008057A (es) 2004-10-15
US20020197327A1 (en) 2002-12-26
CA2440069A1 (en) 2002-09-12
BR0207932A (pt) 2004-03-02
WO2002069939A3 (en) 2003-03-13
WO2002069939A2 (en) 2002-09-12
AU2002254036A1 (en) 2002-09-19
EP1370247B1 (de) 2008-04-09
HK1058482A1 (en) 2004-05-21

Similar Documents

Publication Publication Date Title
DE60226012D1 (de) Geschmacksmaskierte pharmazeutische formulierungen
WO2002011702A3 (en) Hydrogel-driven drug dosage form
YU35302A (sh) Dozirani oblik leka sa inicijalnim hidrogelom
AP1748A (en) Chronotherapeutic dosage forms.
SE9704869D0 (sv) New pharmaceutical formulaton II
HUP0301887A3 (en) Multi-particulate form of medicament, comprising at least two differently coated forms of pellet
WO2004056337A3 (en) Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
ID27504A (id) Formulasi oral baru
BR0109925A (pt) Composição de revestimento para mascaramento de paladar
DK1276470T3 (da) Smagskaskerende overtrækssammensætning
WO2001062236A3 (en) New drug combinations comprising a norepinephrine reuptake inhibitor and an antimuscarinic agent
DE69721845D1 (de) Orale morphinzubereitung in teilchenform
ATE286387T1 (de) Clarithromycin enthaltende zubereitung mit verlängerter freisetzung
WO2005009410A3 (en) Pharmaceutical compositions having a swellable coating
WO2005027843A3 (en) Chronotherapeutic dosage forms
DE60039357D1 (de) Pharmazeutische zusammensetzung enthaltend tadalafil
NO20031409L (no) Ionestyrkeuavhengig farmasoytiske preparat med langvarig frigivelse
WO2004052345A8 (en) Coating composition for taste masking coating and methods for their application and use
ITMI20001093A0 (it) Composizioni a rilascio controllato contenenti un principio attivo, preferibilmente melatonina, e processo di preparazione delle stesse.
EA200300110A1 (ru) Композиция элетриптана в виде частиц
CL2012000406A1 (es) Gránulo de liberación controlada que comprende una partícula central que contiene al isómero r-lansoprazol y una capa de recubrimiento de liberación controlada soluble dependiente del ph seleccionada de copolímeros s y l del ácido metacrílico (div. sol. nº 2051-2003).
NO20040205L (no) Farmasøytiske preparater inneholdende ionebytterharpikser belagt med virksomt stoff
WO2002062299A3 (en) Improved controlled release oral dosage form
AR033431A1 (es) Composiciones farmaceuticas de sabor enmascarado.
WO2003105811A8 (en) PROGRESSIVE RELEASE COMPOSITIONS AND METHOD OF USE

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties